I agree. I think the fact that they have made an upfront payment shows the technology works and has a significant advantage over current methods. Hopefully this should help other pharma companies take notice and will certainly encourage other researchers to at least trial the affirmers. I wonder what the update in August will show.
The agreement signed in May between Activa and Moderna Therapeuticc of America looks to have been very significant. The Wall Street Journal has just valued Moderna at $3 billion.Moderna is a private company and has investors including AstraZeneca,Alexion Pharmaceuticals and Viking Global Investors.For them to choose Avacta technology to investigate is a tremendous compliment to a small British company.
As new investor today passing in thoughts that there can be few companies within the sector with such a fine potential . Albeit an uphill slow .. But in Yorkshire they're used to graft?!? Look forward to seeing this with an upside .
Looks like the last of the tumbleweed just rolled into the distance and we have a board going again! Good to see a bit of an upturn today too. I'm holding long term on this one, just covered my dealing costs today so we're in the right direction. Slow and steady wins the race. Been messing about with UKOG and SXX too at the moment but their boards are full of *****in'. Don't let that happen on here please. Cheers all!
If you go on line and look up ..Moderna Therapeutics..you will see that they are one of the top rated biotech companies in America.The agreement reached with them by Avacta calls for a down payment of $500,000 with potential royalties in the tens of million of dollars as quoted by Alastair Smith,the CEO. of Avacta.
Only Henderson seem to have realised the importance of this.They bought 16.5 % of the company in May. Be happy
Avacta Life Sciences are reducing animal use in the biosciences through the production of Affimers. Affimers are an antibody alternative that are produced wholly in vitro, thus negating the need for animals. In support of these principles we have recently partnered with NC3Rs, the UK-based scientific organisation dedicated to the replacement, reduction and refinement of animal use in research and testing.
NC3Rs are now offering funding through their commercial innovation platform CRACK IT for collaborative partners who wish to utilise Affimers within their own research in the place of antibodies or for testing Affimers in new applications and platforms. Applications for funding your research using Affimers can be made at any time within the next six months and can support projects for up to 12 months, using either off-the-shelf Affimers or bespoke Affimer reagents generated through custom screens.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.